Dyadic International (DYAI) Q3 2024 earnings summary

Executive summary

• Achieved Q3 2024 revenue of $1.96 million, up from $397,000 year-over-year, driven by licensing and milestone payments, including from Proliant and Inzyme, and expansion in alternative proteins, animal health, and biopharmaceuticals.

• Net loss narrowed to $203,000 ($0.01/share) from $1.61 million ($0.06/share) year-over-year, reflecting higher revenue and lower R&D expenses.

• Strategic partnerships and collaborations advanced vaccine, therapeutic, and enzyme development, with major agreements signed with Proliant and Inzyme.

• Expanded product portfolio with new recombinant proteins for molecular biology, cell culture, and animal-free dairy, with several products nearing commercialization and sampling underway.

• Issued $6 million in senior secured convertible notes in March 2024, strengthening liquidity for commercialization and R&D.

Financial highlights

• Q3 2024 revenue: $1.96 million (Q3 2023: $397,000); 9M 2024 revenue: $2.68 million (9M 2023: $2.21 million).

• Net loss for Q3 2024: $203,000 (Q3 2023: $1.61 million); 9M 2024 net loss: $4.26 million (9M 2023: $4.72 million).

• R&D expenses decreased to $460,000 from $716,000 year-over-year, reflecting reduced internal research activity.

• G&A expenses were $1.3 million, up 1.2% year-over-year.

• Cash and investment-grade securities totaled $10 million as of September 30, 2024, up from $7.3 million at year-end 2023.

Outlook and guidance

• Management expects existing cash, investments, and convertible note proceeds to fund operations for at least the next 12 months, with significantly reduced cash burn for 2024 estimated at $4.7 million.

• Anticipated product launches in 2025, including recombinant serum albumin and DNASE-1, and further expansion of enzyme and protein portfolios.

• Ongoing pursuit of non-dilutive funding and new collaborations in human and animal health.